Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259073 | 0.82 | TSHR (0.50) | AHRALDH1A1TSHR | |
| SCHEMBL16951328 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TSHRNFE2L2 | |
| SCHEMBL3068309 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TSHRNFE2L2 | |
| SCHEMBL29937848 | 0.76 | HSD17B10 (0.42) | AHRALDH1A1RAPGEF4EPAS1 | |
| SCHEMBL224110 | 0.76 | HSD17B10 (0.42) | AHRALDH1A1RAPGEF4EPAS1 | |
| SCHEMBL16957879 | 0.76 | AHR (0.33) | AHRRAPGEF4TSHRNFE2L2 | |
| SCHEMBL16618475 | 0.76 | RAPGEF4 (0.36) | AHRRAPGEF4TSHRNFE2L2 | |
| SCHEMBL22423605 | 0.76 | AHR (0.33) | AHRRAPGEF4EPAS1TSHRNFE2L2 | |
| SCHEMBL15741519 | 0.73 | AHR (0.31) | AHRRAPGEF4 | |
| SCHEMBL15741471 | 0.73 | AHR (0.37) | AHRRAPGEF4EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4127039-B1 | HIGH DARKNESS AND HIGH GLOSS DIMENSIONALLY STABLE THERMOPLASTIC SMMA MOLDING COMPOSITION | INEOS STYROLUTION GROUP GMBH (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| EP-4251696-B1 | UV RESISTANT SMMA COPOLYMERS WITH LOW HAZE AND HIGH CLARITY | INEOS STYROLUTION GROUP GMBH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240317968-A1 | HIGH CLARITY AND LOW HAZE UV STABILIZED STYRENE AND METHYL METHACRYLATE COPOLYMERS | INEOS STYROLUTION GROUP GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-118541370-A | Azaindole derivatives and their use as ERK kinase inhibitors | AGV探索公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118234789-A | High clarity, low haze and UV stable styrene-methyl methacrylate copolymers | 英力士苯领集团股份公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240010825-A1 | UV RESISTANT SMMA COPOLYMERS WITH LOW HAZE AND HIGH CLARITY | INEOS STYROLUTION GROUP GMBH (DE) | 2024-01-11 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| EP-3105267-B1 | USE OF METHYL METHACRYLATE VINYLAROMATE COPOLYMERS | INEOS STYROLUTION GROUP GMBH (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-10150830-B2 | Methyl methacrylate vinylaromate copolymers | INEOS STYROLUTION GROUP GMBH (DE) | 2018-12-11 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| EP-3105267-A1 | METHYL METHACRYLATE VINYLAROMATE COPOLYMERS | INEOS Styrolution Group GmbH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355625-A1 | METHYL METHACRYLATE VINYLAROMATE COPOLYMERS | HSBC CORPORATE TRUSTEE COMPANY (UK) LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| WO-2015118142-A1 | METHYL METHACRYLATE VINYLAROMATE COPOLYMERS | STYROLUTION GROUP GMBH (DE) | 2015-08-13 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| WO-2008156817-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | AHR 788/4885ALDH1A1 278/4885RAPGEF4 4265/4885 |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | AHR 1747/4885ALDH1A1 843/4885RAPGEF4 371/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | AHR 1576/4885ALDH1A1 1307/4885RAPGEF4 273/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | AHR 334/4885ALDH1A1 625/4885RAPGEF4 4199/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | AHR 1747/4885ALDH1A1 843/4885RAPGEF4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.